Asset
OLINCIGUAT
CYCLERION THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03285178 | phase2 | completed | 2017-12-22 | 2020-07-22 | Cyclerion Therapeutics | A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) |
| NCT02792998 | phase1 | completed | 2016-05-01 | 2016-11-01 | Cyclerion Therapeutics | A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects |
| NCT03892499 | phase1 | completed | 2019-05-03 | 2019-06-23 | Cyclerion Therapeutics | A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers |
| NCT02931565 | phase2 | terminated | 2017-04-06 | 2018-05-01 | Cyclerion Therapeutics | Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia |
| NCT02572349 | phase1 | completed | 2015-10-01 | 2015-12-01 | Cyclerion Therapeutics | Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.